171 results on '"Raval, Aparna"'
Search Results
2. Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma
3. Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study
4. Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B‐Cell Lymphoma: Results from a Phase 1b Study
5. P-360 Exploring the role of the polycomb repressive complex 2 in high-risk multiple myeloma
6. Data from Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade
7. Supplementary Figures from Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade
8. Supplementary Data from Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade
9. Data from CpG Island Methylation and Expression of the Secreted Frizzled-Related Protein Gene Family in Chronic Lymphocytic Leukemia
10. Supplementary Methods, Materials, Tables 1-2 from CpG Island Methylation and Expression of the Secreted Frizzled-Related Protein Gene Family in Chronic Lymphocytic Leukemia
11. Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM.
12. Reduced rRNA expression and increased rDNA promoter methylation in CD34+ cells of patients with myelodysplastic syndromes
13. Epigenetic Changes during Disease Progression in a Murine Model of Human Chronic Lymphocytic Leukemia
14. Biomarker Analysis of a Phase Ia/Ib Open-Label, Multicentre Study of Tiragolumab or Tiragolumab + Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)
15. P-071: Multi-omic analysis of the tumor microenvironment reveals novel associations in a clinical trial of atezolizumab ± daratumumab for relapsed/refractory multiple myeloma
16. Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma
17. RRMM and Post-BCMA Treated Subjects from the CC-220-MM-001 Study Show Increased Genomic Aberrations Associated with High-Risk and Significant Dysfunction in CD4+ T-Cell Compartment Compared to NDMM Subjects
18. Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade
19. Bone morphogenetic protein 3B silencing in non-small-cell lung cancer
20. Predictive Biomarkers of Response to Venetoclax in Combination with Cobimetinib in Relapsed/Refractory Multiple Myeloma (RRMM)
21. Safety and Preliminary Efficacy Results from a Phase Ib/II Study of Cobimetinib As a Single Agent and in Combination with Venetoclax with or without Atezolizumab in Patients with Relapsed/Refractory Multiple Myeloma
22. Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer
23. Assay of an Intrinsic Acetyltransferase Activity of the Transcriptional Coactivator CIITA
24. Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes
25. Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform
26. TWIST2 Demonstrates Differential Methylation in Immunoglobulin Variable Heavy Chain Mutated and Unmutated Chronic Lymphocytic Leukemia
27. A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes
28. Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study
29. Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma
30. Generation of human class I major histocompatibility complex activating factor in serum free medium and its partial characterization
31. Resistance of Natural Killer and T Cells to Venetoclax Allows for Combination Treatment with Cancer Immunotherapy Agents
32. An AscI boundary library for the studies of genetic and epigenetic alterations in CpG islands
33. Reversibility of Defective Hematopoiesis Caused by Telomere Shortening in Telomerase Knockout Mice
34. Regulation of Ribosomal Gene Expression in Cancer
35. Interaction of TIF-90 and filamin A in the regulation of rRNA synthesis in leukemic cells
36. Germline Allele-Specific Expression of DAPK1 in Chronic Lymphocytic Leukemia
37. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia
38. Reactivation of Telomerase in Late Generation Tert−/− Mice Results in Reversal of Anemia
39. Defective Hematopoiesis and Erythroid Differentiation Resulting From Telomerase Deficiency
40. Ribosomal RNA Expression In CD34+ Hematopoietic Progenitor Cells Inversely Correlates with Ribosomal DNA Methylation In Myelodysplastic Syndromes.
41. Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors
42. NPM1 Haploinsufficiency Results in Increased Numbers of Hematopoietic Stem Cells and Progenitor Cells.
43. CpG Island Methylation in a Mouse Model of Lymphoma Is Driven by the Genetic Configuration of Tumor Cells
44. Downregulation of Death-Associated Protein Kinase 1 (DAPK1) in Chronic Lymphocytic Leukemia
45. CpG Island Methylation and Expression of the Secreted Frizzled-Related Protein Gene Family in Chronic Lymphocytic Leukemia
46. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia
47. CpG Island Methylation in a Mouse Model of Lymphoma Is Driven by the Genetic Configuration of Tumor Cells
48. Global Assessment of Promoter Methylation in a Murine Model of Cancer Identifies ID4 as a Putative Novel Tumor Suppressor Gene in Human Leukemia.
49. Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets
50. Distinct Transcriptional Pathways Regulate Basal and Activated Major Histocompatibility Complex Class I Expression
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.